Michael Xiang1, Gregory M Heestand2, Daniel T Chang3, Erqi L Pollom4. 1. Department of Radiation Oncology, Stanford University, United States; Affiliated Physician, Palo Alto Veterans Affairs Hospital, United States. 2. Department of Medicine, Division of Oncology, Stanford University, United States. 3. Department of Radiation Oncology, Stanford University, United States. Electronic address: dtchang@stanford.edu. 4. Department of Radiation Oncology, Stanford University, United States; Affiliated Physician, Palo Alto Veterans Affairs Hospital, United States. Electronic address: erqiliu@stanford.edu.
Abstract
BACKGROUND AND PURPOSE: The optimal neoadjuvant approach in patients with resectable pancreas cancer is unclear. We investigated outcomes after preoperative chemotherapy alone, chemotherapy with conventionally-fractionated radiation (CFRT), or chemotherapy with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: The NCDB was queried for patients with resectable pancreatic adenocarcinoma (pretreatment stage T1-3, N0-1, M0) who received preoperative, multiagent chemotherapy and definitive surgery from 2010 to 2015. CFRT was 40-60 Gy in 20-35 fractions. SBRT was 20-25 Gy in 1 fraction or 30-50 Gy using at least 5 Gy per fraction. Multivariable regression and propensity score matching were used to adjust for potential confounders, including age, comorbidity score, and pretreatment extent of disease. The primary outcome was overall survival measured from surgery. RESULTS: In total, 1355 patients received preoperative chemotherapy alone, 552 patients received preoperative chemotherapy with CFRT, and 175 patients received preoperative chemotherapy with SBRT. Receipt of SBRT was associated with significantly improved overall survival compared to chemotherapy alone (median 30 vs 21 months, p = 0.02; adjusted hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.47-0.90, p = 0.01). Similarly, SBRT was associated with significantly improved overall survival compared to CFRT (median 29 vs 16 months, p = 0.002; adjusted HR 0.53, 95% CI 0.37-0.76, p = 0.001). Additionally, SBRT was associated with significantly increased rates of pathological complete response and margin-negative resection. Rates of postoperative readmissions and mortality were comparable. CONCLUSIONS: Neoadjuvant chemotherapy with SBRT is associated with favorable survival and pathological outcomes, warranting consideration for prospective validation.
BACKGROUND AND PURPOSE: The optimal neoadjuvant approach in patients with resectable pancreas cancer is unclear. We investigated outcomes after preoperative chemotherapy alone, chemotherapy with conventionally-fractionated radiation (CFRT), or chemotherapy with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: The NCDB was queried for patients with resectable pancreatic adenocarcinoma (pretreatment stage T1-3, N0-1, M0) who received preoperative, multiagent chemotherapy and definitive surgery from 2010 to 2015. CFRT was 40-60 Gy in 20-35 fractions. SBRT was 20-25 Gy in 1 fraction or 30-50 Gy using at least 5 Gy per fraction. Multivariable regression and propensity score matching were used to adjust for potential confounders, including age, comorbidity score, and pretreatment extent of disease. The primary outcome was overall survival measured from surgery. RESULTS: In total, 1355 patients received preoperative chemotherapy alone, 552 patients received preoperative chemotherapy with CFRT, and 175 patients received preoperative chemotherapy with SBRT. Receipt of SBRT was associated with significantly improved overall survival compared to chemotherapy alone (median 30 vs 21 months, p = 0.02; adjusted hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.47-0.90, p = 0.01). Similarly, SBRT was associated with significantly improved overall survival compared to CFRT (median 29 vs 16 months, p = 0.002; adjusted HR 0.53, 95% CI 0.37-0.76, p = 0.001). Additionally, SBRT was associated with significantly increased rates of pathological complete response and margin-negative resection. Rates of postoperative readmissions and mortality were comparable. CONCLUSIONS: Neoadjuvant chemotherapy with SBRT is associated with favorable survival and pathological outcomes, warranting consideration for prospective validation.
Authors: Quisette P Janssen; Jacob L van Dam; Laura R Prakash; Deesje Doppenberg; Christopher H Crane; Casper H J van Eijck; Susannah G Ellsworth; William R Jarnagin; Eileen M O'Reilly; Alessandro Paniccia; Marsha Reyngold; Marc G Besselink; Matthew H G Katz; Ching-Wei D Tzeng; Amer H Zureikat; Bas Groot Koerkamp; Alice C Wei Journal: J Natl Compr Canc Netw Date: 2022-07 Impact factor: 12.693
Authors: Asmita Chopra; Jacob C Hodges; Adam Olson; Steve Burton; Susannah G Ellsworth; Nathan Bahary; Aatur D Singhi; Brian A Boone; Joal D Beane; David Bartlett; Kenneth K Lee; Melissa E Hogg; Michael T Lotze; Alessandro Paniccia; Herbert Zeh; Amer H Zureikat Journal: Ann Surg Oncol Date: 2020-11-24 Impact factor: 4.339
Authors: Eva Versteijne; Ignace H J T de Hingh; Marjolein Y V Homs; Martijn P W Intven; Joost M Klaase; Hjalmar C van Santvoort; Judith de Vos-Geelen; Johanna W Wilmink; Geertjan van Tienhoven Journal: Front Oncol Date: 2022-02-14 Impact factor: 6.244
Authors: Quisette P Janssen; Jacob L van Dam; Isabelle G Kivits; Marc G Besselink; Casper H J van Eijck; Marjolein Y V Homs; Joost J M E Nuyttens; Hongchao Qi; Hjalmar J van Santvoort; Alice C Wei; Roeland F de Wilde; Johanna W Wilmink; Geertjan van Tienhoven; Bas Groot Koerkamp Journal: Ann Surg Oncol Date: 2021-06-17 Impact factor: 5.344